Tag: WuXi Biologics

WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility

SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the...

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

WuXi Biologics’ WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale

Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous...

WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication

Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats.Finished building will be one of...

WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics

Best ESG rating tier of negligible-risk with a top 1% global ranking scoreIndustry and Regional ESG Top-Rated Company for five consecutive yearsLeader in Green...

WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu

The microbial manufacturing site in Chengdu will be equipped with a 15,000L fermenter, enabling the production of 80 to 110 drug substance (DS) batches...

- A word from our sponsors -

HomeTagsWuXi Biologics

STATEMENT – Feds prioritize kids over big tech profits: CMA

SIR Royalty Income Fund Announces June 2026 Distribution

Canada Nickel Completes Upsized Non-Brokered Private Placement of Flow-Through Shares and Provides Corporate Update

Tag: WuXi Biologics

WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

WuXi Biologics’ WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale

WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication

WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics

WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu

Explore

Press Releases

News & Opinion

Living

Others

Follow us